ABSTRACT
Our understanding of how steroid hormones regulate physiological functions has been significantly advanced by structural biology approaches. However, progress has been hampered by misfolding of the ligand binding domains in heterologous expression systems and by conformational flexibility that interferes with crystallization. Here, we show that protein folding problems that are common to steroid hormone receptors are circumvented by mutations that stabilize well-characterized conformations of the receptor. We use this approach to present the structure of an apo steroid receptor that reveals a ligand-accessible channel allowing soaking of preformed crystals. Furthermore, crystallization of different pharmacological classes of compounds allowed us to define the structural basis of NFkappaB-selective signaling through the estrogen receptor, thus revealing a unique conformation of the receptor that allows selective suppression of inflammatory gene expression. The ability to crystallize many receptor-ligand complexes with distinct pharmacophores allows one to define structural features of signaling specificity that would not be apparent in a single structure.
Subject(s)
Bridged Bicyclo Compounds/chemistry , NF-kappa B/chemistry , Pyrazoles/chemistry , Pyrimidines/chemistry , Receptors, Estrogen/chemistry , Binding Sites , Bridged Bicyclo Compounds/pharmacology , Crystallography, X-Ray , Humans , Hydrogen Bonding , Ligands , Models, Molecular , Mutation , NF-kappa B/drug effects , Protein Conformation , Protein Folding , Protein Structure, Secondary , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Receptors, Estrogen/agonists , Sensitivity and Specificity , Signal Transduction , Structure-Activity RelationshipABSTRACT
To increase the chemical diversity of bioactive molecules by incorporating unusual elements, we have examined the replacement of a C=C double bond with the isoelectronic, isostructural B-N bond in the context of nonsteroidal estrogen receptor (ER) ligands. While the B-N bond was hydrolytically labile in the unhindered cyclofenil system, the more hindered anilino dimesitylboranes, analogs of triarylethylene estrogens, were easily prepared, hydrolytically stable, and demonstrated substantial affinity for ERs. X-ray analysis of one ERalpha-ligand complex revealed steric clashes with the para methyl groups distorting the receptor; removal of these groups resulted in an increase in affinity, potency, and transcriptional efficacy. These studies define the structural determinants of stability and cellular bioactivity of a B-N for C=C substitution in nonsteroidal estrogens and provide a framework for further exploration of "elemental isomerism" for diversification of drug-like molecules.
Subject(s)
Boron/chemistry , Carbon/chemistry , Estrogens, Non-Steroidal , Nitrogen/chemistry , Receptors, Estrogen/metabolism , Cell Line, Tumor , Crystallography, X-Ray , Estrogens, Non-Steroidal/chemical synthesis , Estrogens, Non-Steroidal/chemistry , Estrogens, Non-Steroidal/pharmacology , Humans , Isomerism , Ligands , Models, Molecular , Molecular Structure , Protein Binding , Radioligand AssayABSTRACT
The steroid hormone receptors are characterized by binding to relatively rigid, inflexible endogenous steroid ligands. Other members of the nuclear receptor superfamily bind to conformationally flexible lipids and show a corresponding degree of elasticity in the ligand-binding pocket. Here, we report the X-ray crystal structure of the oestrogen receptor alpha (ERalpha) bound to an oestradiol derivative with a prosthetic group, ortho- trifluoromethlyphenylvinyl, which binds in a novel extended pocket in the ligand-binding domain. Unlike ER antagonists with bulky side groups, this derivative is enclosed in the ligand-binding pocket, and acts as a potent agonist. This work shows that steroid hormone receptors can interact with a wider array of pharmacophores than previously thought through structural plasticity in the ligand-binding pocket.
Subject(s)
Estradiol/metabolism , Estrogen Receptor alpha/chemistry , Estrogen Receptor alpha/metabolism , Cell Line, Tumor , Crystallography, X-Ray , Estradiol/chemistry , Humans , Ligands , Models, Molecular , Protein Binding , Protein Structure, Secondary , Protein Structure, TertiaryABSTRACT
2,3-Diarylpyrazolo[1,5-a]pyrimidines are estrogen receptor (ER) antagonists of modest potency that we have described previously. Guided by the crystal structure of an ER-ligand complex that we have obtained with one of these compounds, we prepared analogs that contain a basic side chain at the 2- or 3-aryl group and quickly found one that, according to the structure-based prediction, shows an increase in binding affinity and antagonist potency and a loss of residual agonist activity.
